Startups
2015
AELIX THERAPEUTICS SLDeveloping novel vaccines to cure HIV infection
HTI immunogen: a new therapeutic vaccine against HIV
HTI immunogen: a new therapeutic vaccine against HIV
Address
Carrer de Baldiri Reixac 10, 08028 Barcelona, Spain
Finance Data
| Date | Investors | Amount | Stage | |
| Sep 2021 | 1.700.000 € | Seed | ||
| Jan 2016 | 10.000.000 € | Series A |
Financial Overview
No revenue recorded yet
CERCA ownership
Badalona, Spain
1995
Institut de Recerca de la Sida (IRSICAIXA)
Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.
Product description
The unique and proprietary HTI immunogen sequence was designed by AELIX Therapeutics’ founders and is being delivered to the body by multiple viral and non-viral vectors. GMP-grade clinical trial supplies have been manufactured. AELIX-002, the first clinical trial run by the company, started in September 2017. It is a phase-I randomised, double-blind, placebo-controlled safety, tolerability, and immunogenicity study of the HTI vaccine in early diagnosed, early treated HIV-infected individuals. It evaluates a therapeutic, heterologous prime-boost vaccination regimen using DNA plasmids and an MVA (Modified-Virus-Ankara) vector in the prime phase and a Chimpanzee-Adenovirus (ChAd) and MVA vectors in the booster phase. In a first phase, 15 HIV-infected individuals were included in the trial. Starting in June 2018, 30 additional participants were added to the study, which is still ongoing. After vaccination, the participants are subjected to an analytical anti-retroviral treatment interruption (ATI) to assess their capacity to control viral replication in the absence of anti-retroviral medication. Data from this trial is expected in March 2021.
Company Closed or Exit Year